TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06016426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mass closure vs layer by layer closure of transverse laparotomy incisions in children and infants.
Description: the transverse laparotomy incision in infants and children will be either closed as single layer included the peritoneum, posterior rectus sheath and anterior rectus sheath wit muscle sparing, or the laparotomy will be closed in layer by layer in which the peritoneum and posterior rectus sheath are closed as a layer and the anterior rectus sheath is closed as a seprate layer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mass closure vs layer by layer closure of transverse laparotomy incisions in children and infants.
Description: the transverse laparotomy incision in infants and children will be either closed as single layer included the peritoneum, posterior rectus sheath and anterior rectus sheath wit muscle sparing, or the laparotomy will be closed in layer by layer in which the peritoneum and posterior rectus sheath are closed as a layer and the anterior rectus sheath is closed as a seprate layer.
Study: NCT05465356

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires completed as part of routine care - this is an observational study

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires completed as part of routine care - this is an observational study

Intervention type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview to review factors involved in patients engaging or not-engaging with the digital tools

Intervention type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview to review factors involved in patients engaging or not-engaging with the digital tools
Study: NCT04776590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: neoadjuvant immunotherapy
Study: NCT04673786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P43
Description: 45mg or 90mg dose subcutaneous administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P43
Description: 45mg or 90mg dose subcutaneous administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stelara
Description: 45mg or 90mg dose subcutaneous administration
Study: NCT06099587

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: high-resolution diffusion MRI
Description: The study will combine multi-compartment models (e.g. Archer et al., 2020; Parker et al., 2020) of high-resolution diffusion MRI within medial temporal lobes regions of interest defined through the ASHS algorithm (Yushkevich et al., 2015), with theoretically driven cognitive assessment medial temporal lobes functions. The '4 mountains test' and the 'Memory entities' test will allow specific probing of hippocampal and rhinal cortices functions, respectively (Hartley et al., 2007; Besson et al., 2020).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: high-resolution diffusion MRI
Description: The study will combine multi-compartment models (e.g. Archer et al., 2020; Parker et al., 2020) of high-resolution diffusion MRI within medial temporal lobes regions of interest defined through the ASHS algorithm (Yushkevich et al., 2015), with theoretically driven cognitive assessment medial temporal lobes functions. The '4 mountains test' and the 'Memory entities' test will allow specific probing of hippocampal and rhinal cortices functions, respectively (Hartley et al., 2007; Besson et al., 2020).
Study: NCT06165614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate pessary
Description: Subjects will self-administer 200 mg of Artesunate pessary (vaginal insert) daily for 5 days, on weeks 1, 3, 5, 7.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Colposcopy is a procedure that allows close examination of the cervix, vagina, and vulva, performed on weeks 8 and 14.
Study: NCT05514964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feasibility study
Description: Individuals interested to participate in this study were informed about the intervention via the project website and Facebook page of the project. Prior to the start of the study, participants were invited to read the Informed Consent and express their agreement to participate. Only after the Informed Consent was electronically signed, participants were able to complete the screening questionnaires online.~The intervention program (based on Acceptance and Commitment Therapy) consists of six treatment modules adapted to the online environment. Each module was structured like a therapy session and contained at least two or three homework assignments. Each participant was assigned to an online psychotherapist. At the end of the six modules, participants completed the post-intervention measures.
Study: NCT05040308

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrating PrEP delivery
Description: Integration of PrEP delivery services in NSP and MAT programs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrating PrEP delivery
Description: Integration of PrEP delivery services in NSP and MAT programs
Study: NCT05847998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized measurement of capillary refill time by second generation DICART prototype
Description: Capillary refill time is measured by two independent operators, each one blinded from the other, with second generation DICART prototype.~Each operator performs two series of three consecutive measurement on the finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical measurement of capillary refill time
Description: Capillary refill time is clinically measured by two independent operators, each one blinded from the other.~Each operator performs, two series of three consecutive measurement on the second finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax, inverted relative to DICART measurements.
Study: NCT05838638

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSSET-CINV
Description: Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSSET-CINV
Description: Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
Study: NCT06542315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative parathyroid hormone (IOPTH) monitoring
Description: Intraoperative parathyroid hormone (IOPTH) monitoring, which is a surgical adjunct that permits PTH bloodwork to be drawn during parathyroid surgery to monitor and guide surgical outcomes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative parathyroid hormone (IOPTH) monitoring
Description: Intraoperative parathyroid hormone (IOPTH) monitoring, which is a surgical adjunct that permits PTH bloodwork to be drawn during parathyroid surgery to monitor and guide surgical outcomes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative parathyroid hormone (IOPTH) monitoring
Description: Intraoperative parathyroid hormone (IOPTH) monitoring, which is a surgical adjunct that permits PTH bloodwork to be drawn during parathyroid surgery to monitor and guide surgical outcomes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative parathyroid hormone (IOPTH) monitoring
Description: Intraoperative parathyroid hormone (IOPTH) monitoring, which is a surgical adjunct that permits PTH bloodwork to be drawn during parathyroid surgery to monitor and guide surgical outcomes.
Study: NCT05220605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BromAc
Description: Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BromAc
Description: Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BromAc
Description: Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.
Study: NCT05421910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic training combined with electrical stimulation
Description: Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: robotic training combined with electrical stimulation
Description: Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.
Study: NCT04301141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Assisted Cognitive Behavioural Therapy
Description: The intervention will be delivered in NHS services and will involve using VR to assist the delivery of conventional CBT for the treatment of social anxiety in autistic adolescents. Social situations that are commonly anxiety-evoking for this patient group will be simulated in VR and used for exposure (a typical component of CBT for social anxiety). Therapists will use a modular approach involving optional modules such as psychoeducation on anxiety in the context of ASD, managing expectations of outcome and emotional literacy training. Essential modules include rapport building, introducing the use and purpose of VR, and exposure (incorporating VR). Because CBT is delivered in routine clinical practice, the VR exposure sessions will be the main subject of interest.
Study: NCT04937088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: Liquid aspirin formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA
Description: Liquid aspirin formulation
Study: NCT04884048

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographs
Description: Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographs
Description: Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system
Study: NCT06146725

Intervention type: PROCEDURE
Intervention: Tumor resection
Description: Maximal safe resection of the tumor

Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Biopsy of the tumor
Study: NCT06426069

Intervention type: OTHER
Intervention: Masticatory efficiency assessment
Description: Masticatory efficiency will be assessed for each group.

Intervention type: OTHER
Intervention: Masticatory efficiency assessment
Description: Masticatory efficiency will be assessed for each group.

Intervention type: OTHER
Intervention: Masticatory efficiency assessment
Description: Masticatory efficiency will be assessed for each group.

Intervention type: OTHER
Intervention: Masticatory efficiency assessment
Description: Masticatory efficiency will be assessed for each group.

Intervention type: OTHER
Intervention: Masticatory efficiency assessment
Description: Masticatory efficiency will be assessed for each group.
Study: NCT06095856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaf Gauge
Description: Occlusal device used to locate centric relation of the jaws

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaf Gauge
Description: Occlusal device used to locate centric relation of the jaws

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaf Gauge
Description: Occlusal device used to locate centric relation of the jaws

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lucia Jig
Description: Occlusal device used to locate centric relation of the jaws

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lucia Jig
Description: Occlusal device used to locate centric relation of the jaws

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lucia Jig
Description: Occlusal device used to locate centric relation of the jaws

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kois Deprogrammer
Description: Occlusal device used to locate centric relation of the jaws and deprogram jaw muscles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kois Deprogrammer
Description: Occlusal device used to locate centric relation of the jaws and deprogram jaw muscles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kois Deprogrammer
Description: Occlusal device used to locate centric relation of the jaws and deprogram jaw muscles
Study: NCT04086550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIQOSEAL
Description: Adjunctive bioresorbable patch

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuraSeal, Adherus
Description: synthetic absorbable sealants
Study: NCT06424093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Technology
Description: To evaluate the role of virtual reality technology as distraction technique in the management of acute pain during outpatient hysteroscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Technology
Description: To evaluate the role of virtual reality technology as distraction technique in the management of acute pain during outpatient hysteroscopy
Study: NCT05740228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)
Description: A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal High-Definition (HD) tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)
Description: A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)
Description: A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises.
Study: NCT05051007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
Study: NCT05272033

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Transcutaneous Electrical Acupoint Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Transcutaneous Electrical Acupoint Stimulation
Study: NCT05079607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mitopure Topical Formula 1
Description: topical skin cream containing the low dose mitophagy activator Mitopure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mitopure Topical Formula 2
Description: topical skin cream containing the high dose mitophagy activator Mitopure
Study: NCT05155501

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted radical prostatectomy (RP)
Description: The conventional approach to prostate cancer surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)
Description: A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate.
Study: NCT05300516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vagus nerve-guided group
Description: The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
Study: NCT05242783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin
Description: intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.
Study: NCT06448208

Intervention type: DIAGNOSTIC_TEST
Intervention: positron emission tomography (PET) scans
Description: Before and after treatment.
Study: NCT05110976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.
Study: NCT05350059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound (HIFU) to the Breast Cancer
Description: Breast cancer will be ablated using high intensity frequency ultrasound prior to breast surgery
Study: NCT05296577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib and vinorelbine
Description: anlotinib 12mg orally ,2 weeks on/1 week off ,Q3W; vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vinorelbine injection
Description: vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
Study: NCT04997057

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotics mixture
Description: 12 weeks of daily supplementation with 1 g of probiotics mixture (4.10exp9 colony forming unit/g) containing:~* Bifidobacterium longum LA 101~* Lactobacillus helveticus La 102~* Lactococcus lactis LA 103~* Streptococcus thermophilus LA 104
Study: NCT05218616

Intervention type: DRUG
Group type: OTHER
Intervention: Aviga, capsules 50 mg / Sutent®, capsules 50 mg
Description: Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib / Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib.

Intervention type: DRUG
Group type: OTHER
Intervention: Sutent®, capsules 50 mg / Aviga, capsules 50 mg
Description: Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib / Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib